<?xml version="1.0" encoding="UTF-8"?>
<results title="testTrace">
 <result pre="potential of repurposing clinically approved drugs for possible prevention and" exact="treatment" post="of ZIKV infection and its associated disease. Although emerging"/>
 <result pre="clinically approved drugs for possible prevention and treatment of ZIKV" exact="infection" post="and its associated disease. Although emerging infectious diseases have"/>
 <result pre="rapid approach for emerging and reemerging pathogens. Compared with conventional" exact="screening" post="of compound libraries for inhibitors, drug repurposing has the"/>
 <result pre="found that human primary astrocytes are more susceptible to ZIKV" exact="infection" post="than several other human cell types, including fetal microglia,"/>
 <result pre="fetal microglia, fetal neuron, and neural progenitor cells. Using ZIKV" exact="infection" post="of astrocytes as a screening assay, they identified rilpivirine"/>
 <result pre="neural progenitor cells. Using ZIKV infection of astrocytes as a" exact="screening" post="assay, they identified rilpivirine as a ZIKV inhibitor from"/>
 <result pre="higher susceptibility of astrocytes than other cell types to ZIKV" exact="infection" post="is intriguing because previous studies suggested that ZIKV preferentially"/>
 <result pre="is essential to gauge potential adverse effect caused by non-specific" exact="infection" post="and killing of non-tumor cells. It remains to be"/>
 <result pre="and neurons, but not neural progenitor cells.Ã‚ In addition, ZIKV" exact="infection" post="caused significant inflammation and abundant apoptotic/necrotic cell damage. Treatment"/>
 <result pre="replication and disease development. However, it was notable that compound" exact="treatment" post="did not completely prevent weight loss or brain inflammation,"/>
 <result pre="provided a good example of repurposing clinical drugs for potential" exact="treatment" post="of ZIKV infection. For any repurposed drug to work,"/>
 <result pre="from the Global Virus NetworkAntiviral Res.144201722324628595824 2SariyerI.K.GordonJ.BurdoT.H.WolleboH.GiantiE.DonadoniM.BellizziA.CicaleseS.LoomisR.RobinsonJ.A.Suppression of Zika virus" exact="infection" post="in the brain by the antiretroviral drug rilpivirineMol. Ther.27201920672079this"/>
 <result pre="InfectionCell Host Microbe20201625927027476412 5XuM.LeeE.M.WenZ.ChengY.HuangW.K.QianX.TcwJ.KouznetsovaJ.OgdenS.C.HammackC.Identification of small-molecule inhibitors of Zika virus" exact="infection" post="and induced neural cell death via a drug repurposing"/>
</results>
